Literature DB >> 7051384

Cervical Interbody fusion using calf bone.

E B Siqueira, L I Kranzler.   

Abstract

Since 1972, Kiel Surgibone (calf bone) dowels have been inserted in the cervical intervertebral space of 221 patients. The anterior approach was used for cervical interbody fusion. Fusion occurred in every patient who survived long enough for it to occur. No complications occurred that specifically could be attributed to use of this type of grafting material. Kiel surgibone has the advantage of eliminating the need for osteotomy when autologous bone is used or for a bone bank when homologous bone is employed. Kiel Surgibone is supplied sterile and is precisely preshaped.

Entities:  

Mesh:

Year:  1982        PMID: 7051384     DOI: 10.1016/0090-3019(82)90010-6

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  6 in total

1.  Morbidity after anterior cervical decompression and fusion. The influence of the donor site on recovery, and the results of a trial of surgibone compared to autologous bone.

Authors:  J N Rawlinson
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 2.  Manufacturing artificial bone allografts: a perspective.

Authors:  Emma Steijvers; Armaan Ghei; Zhidao Xia
Journal:  Biomater Transl       Date:  2022-03-28

3.  Diagnosing cervical fusion: a comprehensive literature review.

Authors:  Nanin Sethi; James Devney; Holly L Steiner; K Daniel Riew
Journal:  Asian Spine J       Date:  2008-12-31

Review 4.  Bone graft substitutes in anterior cervical discectomy and fusion.

Authors:  Anthony M T Chau; Ralph J Mobbs
Journal:  Eur Spine J       Date:  2009-01-17       Impact factor: 3.134

Review 5.  Current concepts of anterior cervical discectomy and fusion: a review of literature.

Authors:  Kyung-Jin Song; Byeong-Yeol Choi
Journal:  Asian Spine J       Date:  2014-08-19

Review 6.  Bone substitutes in orthopaedic surgery: from basic science to clinical practice.

Authors:  V Campana; G Milano; E Pagano; M Barba; C Cicione; G Salonna; W Lattanzi; G Logroscino
Journal:  J Mater Sci Mater Med       Date:  2014-05-28       Impact factor: 3.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.